1
|
Bouhniz OE, Kenani A. Potential role of genetic polymorphisms in neoadjuvant chemotherapy response in breast cancer. J Chemother 2024:1-15. [PMID: 38511398 DOI: 10.1080/1120009x.2024.2330241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2023] [Accepted: 03/11/2024] [Indexed: 03/22/2024]
Abstract
Chemoresistance leads to treatment failure, which can arise through different mechanisms including patients' characteristics. Searching for genetic profiles as a predictor for drug response and toxicity has been extensively studied in pharmacogenomics, thus contributing to personalized medicine and providing alternative treatments. Numerous studies have demonstrated significant evidence of association between genetic polymorphisms and response to neoadjuvant chemotherapy (NAC) in breast cancer. In this review, we explored the potential impact of genetic polymorphisms in NAC primary resistance through selecting a specific clinical profile. The genetic variability within pharmacokinetics, pharmacodynamics, DNA synthesis and repair, and oncogenic signaling pathways genes could be predictive or prognostic markers for NAC resistance. The clinical implication of these results can help provide individualized treatment plans in the early stages of breast cancer treatment. Further studies are needed to determine the genetic hosts of primary chemoresistance mechanisms in order to further emphasize the implementation of genotypic approaches in personalized medicine.
Collapse
Affiliation(s)
- Om Elez Bouhniz
- Research Laboratory "Environment, Inflammation, Signaling and Pathologies" (LR18ES40), Faculty of Medicine of Monastir, University of Monastir, Monastir, Tunisia
| | - Abderraouf Kenani
- Research Laboratory "Environment, Inflammation, Signaling and Pathologies" (LR18ES40), Faculty of Medicine of Monastir, University of Monastir, Monastir, Tunisia
| |
Collapse
|
2
|
Ahmadi S, Surmava S, Kvaratskhelia D, Gogolashvili A, Kvaratskhelia E, Abzianidze E, Kankava K. Association Between Multiple Single Nucleotide Polymorphisms in Folate Metabolism Pathway and Breast Cancer Risk in Georgian Women: A Case-Control Study. Clin Med Insights Oncol 2024; 18:11795549241233693. [PMID: 38433849 PMCID: PMC10908228 DOI: 10.1177/11795549241233693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Accepted: 02/01/2024] [Indexed: 03/05/2024] Open
Abstract
Background The folate metabolism pathway plays an integral part in DNA synthesis, methylation, and repair. Methylenetetrahydrofolate reductase (MTHFR) and methylenetetrahydrofolate dehydrogenase (MTHFD1) are both enzymes that are involved in this pathway, and the single nucleotide polymorphisms (SNPs) in genes coding for them have modulatory effects on DNA expression. This study aimed to investigate the relationship between MTHFR C677T (rs1801133) and MTHFD1 G1958A (rs2236225) polymorphisms and the risk of developing breast cancer in Georgian women. Methods A case-control study was performed examining the MTHFR C677T and MTHFD1 G1958A SNP in breast cancer-confirmed cases and healthy matched controls. Real time-polymerase chain reaction (PCR) was used to genotype SNPs. The case individuals' pathology reports were obtained following surgeries for cancer characteristic data. Statistical analysis was performed to investigate the significance of the acquired data. Results Statistical analysis of MTHFR C677T SNP revealed that the CT genotype increased the risk of breast cancer by 2.17 folds in the over-dominant model. Statistical analysis of MTHFD1 G1958A SNP showed that the GA genotype increased the risk of breast cancer by 4.12 folds in the codominant model and 2.41 folds in the over-dominant model. No statistically significant link was found between genotypes and lymph node status, however, patients with the CT genotype had higher percentages of proliferative activity. Conclusions Breast cancer seems to have a statistically significant association with the CT genotype in MTHFR C677T and the GA genotype in MTHFD1 G1958A in Georgian women.
Collapse
Affiliation(s)
- Saba Ahmadi
- Department of Molecular and Medical Genetics, Tbilisi State Medical University, Tbilisi, Georgia
| | - Sandro Surmava
- Department of Molecular and Medical Genetics, Tbilisi State Medical University, Tbilisi, Georgia
| | - Davit Kvaratskhelia
- Department of Molecular and Medical Genetics, Tbilisi State Medical University, Tbilisi, Georgia
| | - Ana Gogolashvili
- Department of Molecular and Medical Genetics, Tbilisi State Medical University, Tbilisi, Georgia
| | - Eka Kvaratskhelia
- Department of Molecular and Medical Genetics, Tbilisi State Medical University, Tbilisi, Georgia
- V. Bakhutashvili Institute of Medical Biotechnology, Tbilisi State Medical University, Tbilisi, Georgia
| | - Elene Abzianidze
- Department of Molecular and Medical Genetics, Tbilisi State Medical University, Tbilisi, Georgia
- Ivane Beritashvili Center Of Experimental Biomedicine, Tbilisi, Georgia
| | - Ketevani Kankava
- Department of Molecular and Medical Genetics, Tbilisi State Medical University, Tbilisi, Georgia
| |
Collapse
|
3
|
Gimenez-Martins APD, Castanhole-Nunes MMU, Nascimento-Filho CHVD, Santos SPD, Galbiatti-Dias ALS, Fernandes GMDM, Cuzziol CI, Francisco JLE, Pavarino ÉC, Goloni-Bertollo EM. Association between folate metabolism polymorphisms and breast cancer: a case-control study. Genet Mol Biol 2021; 44:e20200485. [PMID: 34699584 PMCID: PMC8547389 DOI: 10.1590/1678-4685-gmb-2020-0485] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2021] [Accepted: 08/08/2021] [Indexed: 12/12/2022] Open
Abstract
We investigated the association between methylenetetrahydrofolate reductase (MTHFR C677T and A1298C), methionine synthetase (MTR A2756G), and methionine synthase reductase (MTRR A66G) polymorphisms involved in folate pathway and breast cancer risk, and the interaction between these polymorphisms and tobacco and alcohol consumption. Furthermore, we evaluated the association between these polymorphisms and clinicopathological variables. This case-control study included 606 Brazilian women, comprising 128 patients with breast cancer and 478 controls. MTHFR and MTR polymorphisms were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and MTRR polymorphisms using real-time PCR. Age ≥50 years (odds ratio [OR]: 2.65; 95% confidence interval [CI]: 1.65-4.26; p<0.001) and alcohol consumption (OR: 1.76; 95% CI: 1.0-2.85; p=0.021) were associated with an increased risk of breast cancer. For MTHFR A1298C, we observed a reduced risk of developing breast cancer in the codominant model (genotype CC-OR: 0.22; 95% CI: 0.06-0.74; p=0.014), recessive model (OR: 0.22; 95% CI: 0.07-0.76 p=0.004), and log-additive model (OR: 0.70; 95% CI: 0.49-0.98; p=0.035). Women aged ≥50 years and those who are alcohol consumers had increased susceptibility to breast cancer, and MTHFR A1298C modulated the risk for this disease. This is the first study to evaluate the association between polymorphisms in folate metabolism and breast cancer in the northwest region of São Paulo State, Brazil.
Collapse
Affiliation(s)
- Ana Paula D'Alarme Gimenez-Martins
- Faculdade de Medicina de São José do Rio Preto (FAMERP), Departamento de Biologia Molecular, Unidade de Pesquisa em Genética e Biologia Molecular (UPGEM), São José do Rio Preto, SP, Brazil
| | - Márcia Maria Urbanin Castanhole-Nunes
- Faculdade de Medicina de São José do Rio Preto (FAMERP), Departamento de Biologia Molecular, Unidade de Pesquisa em Genética e Biologia Molecular (UPGEM), São José do Rio Preto, SP, Brazil.,Fundação da Faculdade Medicina de São José do Rio Preto (FUNFARME), São José do Rio Preto, SP, Brazil
| | - Carlos Henrique Viesi do Nascimento-Filho
- Faculdade de Medicina de São José do Rio Preto (FAMERP), Departamento de Biologia Molecular, Unidade de Pesquisa em Genética e Biologia Molecular (UPGEM), São José do Rio Preto, SP, Brazil
| | - Stéphanie Piacenti Dos Santos
- Faculdade de Medicina de São José do Rio Preto (FAMERP), Departamento de Biologia Molecular, Unidade de Pesquisa em Genética e Biologia Molecular (UPGEM), São José do Rio Preto, SP, Brazil
| | - Ana Lívia Silva Galbiatti-Dias
- Faculdade de Medicina de São José do Rio Preto (FAMERP), Departamento de Biologia Molecular, Unidade de Pesquisa em Genética e Biologia Molecular (UPGEM), São José do Rio Preto, SP, Brazil.,Fundação da Faculdade Medicina de São José do Rio Preto (FUNFARME), São José do Rio Preto, SP, Brazil
| | - Glaucia Maria de Mendonça Fernandes
- Faculdade de Medicina de São José do Rio Preto (FAMERP), Departamento de Biologia Molecular, Unidade de Pesquisa em Genética e Biologia Molecular (UPGEM), São José do Rio Preto, SP, Brazil
| | - Caroline Izak Cuzziol
- Faculdade de Medicina de São José do Rio Preto (FAMERP), Departamento de Biologia Molecular, Unidade de Pesquisa em Genética e Biologia Molecular (UPGEM), São José do Rio Preto, SP, Brazil
| | - José Luis Esteves Francisco
- Faculdade de Medicina de São José do Rio Preto (FAMERP), Departamento de Ginecologia e Obstetrícia, São José do Rio Preto, SP, Brazil.,Fundação da Faculdade Medicina de São José do Rio Preto (FUNFARME), São José do Rio Preto, SP, Brazil
| | - Érika Cristina Pavarino
- Faculdade de Medicina de São José do Rio Preto (FAMERP), Departamento de Biologia Molecular, Unidade de Pesquisa em Genética e Biologia Molecular (UPGEM), São José do Rio Preto, SP, Brazil.,Fundação da Faculdade Medicina de São José do Rio Preto (FUNFARME), São José do Rio Preto, SP, Brazil
| | - Eny Maria Goloni-Bertollo
- Faculdade de Medicina de São José do Rio Preto (FAMERP), Departamento de Biologia Molecular, Unidade de Pesquisa em Genética e Biologia Molecular (UPGEM), São José do Rio Preto, SP, Brazil.,Fundação da Faculdade Medicina de São José do Rio Preto (FUNFARME), São José do Rio Preto, SP, Brazil
| |
Collapse
|
4
|
One-carbon genetic variants and the role of MTHFD1 1958G>A in liver and colon cancer risk according to global DNA methylation. PLoS One 2017; 12:e0185792. [PMID: 28968444 PMCID: PMC5624642 DOI: 10.1371/journal.pone.0185792] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2017] [Accepted: 09/19/2017] [Indexed: 12/11/2022] Open
Abstract
Several polymorphic gene variants within one-carbon metabolism, an essential pathway for nucleotide synthesis and methylation reactions, are related to cancer risk. An aberrant DNA methylation is a common feature in cancer but whether the link between one-carbon metabolism variants and cancer occurs through an altered DNA methylation is yet unclear. Aims of the study were to evaluate the frequency of one-carbon metabolism gene variants in hepatocellular-carcinoma, cholangiocarcinoma and colon cancer, and their relationship to cancer risk together with global DNA methylation status. Genotyping for BHMT 716A>G, DHFR 19bp ins/del, MTHFD1 1958G>A, MTHFR 677C>T, MTR 2756A>G, MTRR 66A>G, RFC1 80G>A, SHMT1 1420C>T, TCII 776C>G and TS 2rpt-3rpt was performed in 102 cancer patients and 363 cancer-free subjects. Methylcytosine (mCyt) content was measured by LC/MS/MS in peripheral blood mononuclear cells (PBMCs) DNA. The MTHFD1 1958AA genotype was significantly less frequent among cancer patients as compared to controls (p = 0.007) and related to 63% reduction of overall cancer risk (p = 0.003) and 75% of colon cancer risk (p = 0.006). When considering PBMCs mCyt content, carriers of the MTHFD1 1958GG genotype showed a lower DNA methylation as compared to carriers of the A allele (p = 0.048). No differences were highlighted by evaluating a possible relationship between the other polymorphisms analyzed with cancer risk and DNA methylation. The MTHFD1 1958AA genotype is linked to a significantly reduced cancer risk. The 1958GG genotype is associated to PBMCs DNA hypomethylation as compared to the A allele carriership that may exert a protective effect for cancer risk by preserving from DNA hypomethylation.
Collapse
|
5
|
van der Merwe N, Peeters AV, Pienaar FM, Bezuidenhout J, van Rensburg SJ, Kotze MJ. Exome Sequencing in a Family with Luminal-Type Breast Cancer Underpinned by Variation in the Methylation Pathway. Int J Mol Sci 2017; 18:E467. [PMID: 28241424 PMCID: PMC5343999 DOI: 10.3390/ijms18020467] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2017] [Revised: 01/31/2017] [Accepted: 02/10/2017] [Indexed: 01/19/2023] Open
Abstract
Panel-based next generation sequencing (NGS) is currently preferred over whole exome sequencing (WES) for diagnosis of familial breast cancer, due to interpretation challenges caused by variants of uncertain clinical significance (VUS). There is also no consensus on the selection criteria for WES. In this study, a pathology-supported genetic testing (PSGT) approach was used to select two BRCA1/2 mutation-negative breast cancer patients from the same family for WES. Homozygosity for the MTHFR 677 C>T mutation detected during this PSGT pre-screen step was considered insufficient to cause bilateral breast cancer in the index case and her daughter diagnosed with early-onset breast cancer (<30 years). Extended genetic testing using WES identified the RAD50 R385C missense mutation in both cases. This rare variant with a minor allele frequency (MAF) of <0.001 was classified as a VUS after exclusion in an affected cousin and extended genotyping in 164 unrelated breast cancer patients and 160 controls. Detection of functional polymorphisms (MAF > 5%) in the folate pathway in all three affected family members is consistent with inheritance of the luminal-type breast cancer in the family. PSGT assisted with the decision to pursue extended genetic testing and facilitated clinical interpretation of WES aimed at reduction of recurrence risk.
Collapse
Affiliation(s)
- Nicole van der Merwe
- Division of Anatomical Pathology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg 7500, South Africa.
| | - Armand V Peeters
- Division of Anatomical Pathology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg 7500, South Africa.
| | | | - Juanita Bezuidenhout
- Division of Anatomical Pathology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg 7500, South Africa.
| | - Susan J van Rensburg
- Division of Chemical Pathology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg 7500, South Africa.
| | - Maritha J Kotze
- Division of Chemical Pathology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg 7500, South Africa.
- National Health Laboratory Service, Tygerberg Hospital, Tygerberg 7500, South Africa.
| |
Collapse
|
6
|
Rezende LM, Marson FAL, Lima CSP, Bertuzzo CS. Can MTHFR C677T and A1298C Polymorphisms Alter the Risk and Severity of Sporadic Breast Cancer in Brazilian Women? Clin Breast Cancer 2017; 17:e199-e208. [PMID: 28330681 DOI: 10.1016/j.clbc.2017.02.004] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2016] [Revised: 02/01/2017] [Accepted: 02/08/2017] [Indexed: 01/11/2023]
Abstract
INTRODUCTION Polymorphisms in the methylenetetrahydrofolate reductase gene (MTHFR) modify the risk and severity of sporadic breast cancer (BC). In this context, the MTHFR C677T and A1298C polymorphisms have been associated with risk and severity of sporadic BC. PATIENTS AND METHODS In total, 253 women with BC and 257 controls were enrolled in this study. Polymorphisms were analyzed using restriction fragment length polymorphism - polymerase chain reaction. Epidemiology, tumor characteristics, and reproductive factors were considered in the analysis. Statistical tests included the χ2 test, the Fisher exact test, and the Mann-Whitney and Kruskal-Wallis tests, or parametric equivalents. RESULTS MTHFR polymorphisms were not a risk factor for BC. The 677CC genotype was associated with distant metastasis (odds ratio [OR] = 5.311; 95% confidence interval [CI] = 1.124-25.09) and lower estrogen receptor expression, whereas the 1298AA genotype was associated with stage 0 (OR = 0.244; 95% CI = 0.077-0.771) and increased estrogen receptor expression. In haplotype analysis, 677CC/1298AA was associated with hypertension (OR = 1.979; 95% CI = 1.036-3.782), and 677CT/1298AC was associated with invasive carcinoma of no special type (OR = 0.472; 95% CI = 0.243-0.918) and stage 0 (OR = 3.476; 95% CI = 1.341-10.47). CONCLUSION The MTHFR C677T and A1298C polymorphisms do not alter the risk of BC, but are associated with the clinical severity of BC.
Collapse
Affiliation(s)
- Luciana Montes Rezende
- Department of Medical Genetics, Faculty of Medical Sciences, State University of Campinas - Unicamp, Cidade Universitária Zeferino Vaz, Campinas/SP, Brasil.
| | - Fernando Augusto Lima Marson
- Department of Medical Genetics, Faculty of Medical Sciences, State University of Campinas - Unicamp, Cidade Universitária Zeferino Vaz, Campinas/SP, Brasil; Department of Pediatrics, Faculty of Medical Sciences, State University of Campinas - Unicamp, Cidade Universitária Zeferino Vaz, Campinas/SP, Brasil.
| | - Carmen Sílvia Passos Lima
- Department of Internal Medicine, Faculty of Medical Sciences, State University of Campinas - Unicamp, Cidade Universitária Zeferino Vaz, Campinas/SP, Brasil
| | - Carmen Sílvia Bertuzzo
- Department of Medical Genetics, Faculty of Medical Sciences, State University of Campinas - Unicamp, Cidade Universitária Zeferino Vaz, Campinas/SP, Brasil
| |
Collapse
|
7
|
Wang P, Li S, Wang M, He J, Xi S. Association of MTRR A66G polymorphism with cancer susceptibility: Evidence from 85 studies. J Cancer 2017; 8:266-277. [PMID: 28243331 PMCID: PMC5327376 DOI: 10.7150/jca.17379] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2016] [Accepted: 11/14/2016] [Indexed: 02/07/2023] Open
Abstract
Methionine synthase reductase (MTRR) is a key regulatory enzyme involved in the folate metabolic pathway. Previous studies investigating the association of MTRR A66G polymorphism with cancer susceptibility reported inconclusive results. We performed the current meta-analysis to obtain a more precise estimation of the possible association. Published literatures were identified from PubMed, Embase and CBM databases up to October 2016. The strength of the association between the MTRR A66G polymorphism and cancer susceptibility was assessed using odds ratios (ORs) and the corresponding 95% confidence intervals (CIs). Eighty five published studies with 32,272 cases and 37,427 controls were included in this meta-analysis. Pooled results indicated that the MTRR A66G polymorphism was associated with an increased overall cancer risk (homozygous model: OR = 1.08, 95% CI = 1.02-1.15, P = 0.009; recessive model: OR = 1.06, 95% CI = 1.00-1.12, P < 0.001 and allele comparison: OR = 1.03, 95% CI = 1.00-1.06, P < 0.001). Stratification analysis further indicated significant associations in head and neck cancer, Caucasians, Africans, and high quality studies. However, to avoid the "false-positive report", the significant findings were assessed by the false-positive report probability (FPRP) test. Interestingly, the results of FPRP test revealed that the increased risk for MTRR A66G polymorphism among Africans need further validation due to the high probabilities of false-positive results. This meta-analysis suggests that the MTRR A66G polymorphism is associated with significantly increased cancer risk, a finding that needs to be confirmed in single large studies.
Collapse
Affiliation(s)
- Ping Wang
- The Key Laboratory of Pharmacology and Medical Molecular Biology, Medical College, Henan University of Science and Technology, Luoyang 471023, Henan, China
| | - Sanqiang Li
- The Molecular Medicine Key Laboratory of Liver Injury and Repair, Medical College, Henan University of Science and Technology, Luoyang 471023, Henan, China
| | - Meilin Wang
- The Key Laboratory of Pharmacology and Medical Molecular Biology, Medical College, Henan University of Science and Technology, Luoyang 471023, Henan, China
| | - Jing He
- Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, China
- ✉ Corresponding authors: Shoumin Xi, The Key Laboratory of Pharmacology and Medical Molecular Biology, Medical College, Henan University of Science and Technology, No. 263 Kaiyuan Avenue, Luoyang 471023, Henan, China, Tel.: (+86-379) 64830346, Fax: (+86-379) 64830345, E-mail: ; or Jing He, Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou 510623, Guangdong, China, Tel./Fax: (+86-20) 38076560, E-mail:
| | - Shoumin Xi
- The Key Laboratory of Pharmacology and Medical Molecular Biology, Medical College, Henan University of Science and Technology, Luoyang 471023, Henan, China
- ✉ Corresponding authors: Shoumin Xi, The Key Laboratory of Pharmacology and Medical Molecular Biology, Medical College, Henan University of Science and Technology, No. 263 Kaiyuan Avenue, Luoyang 471023, Henan, China, Tel.: (+86-379) 64830346, Fax: (+86-379) 64830345, E-mail: ; or Jing He, Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou 510623, Guangdong, China, Tel./Fax: (+86-20) 38076560, E-mail:
| |
Collapse
|
8
|
Suner A, Buyukhatipoglu H, Aktas G, Kus T, Ulasli M, Oztuzcu S, Kalender ME, Sevinc A, Kul S, Camci C. Polymorphisms in the MTHFR gene are associated with recurrence risk in lymph node-positive breast cancer patients. Onco Targets Ther 2016; 9:5603-9. [PMID: 27672331 PMCID: PMC5024764 DOI: 10.2147/ott.s104890] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
Purpose The aim of this study is to clarify the relationship between recurrence risk of breast cancer and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms. Patients and methods Breast cancer patients who had undergone surgery in Gaziantep University Oncology Hospital between June 2005 and June 2012 were followed-up and retrospectively enrolled in this study. Blood samples were collected from all patients to assess MTHFR C677T polymorphisms. Stage according to tumor–node–metastasis system, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 status, grade of disease, menopausal status, and administered chemotherapy or hormonal therapy were recorded. Effects of these parameters on recurrence risk were evaluated using univariate analysis and multivariate binary logistic regression model. Results Association of MTHFR C677T polymorphisms with recurrence risk was evaluated in 298 patients whose median age was 47 years (range: 21–79 years). In all patients, age (odds ratio [OR] =0.953, P=0.005) and N3 lymph node status (OR =6.293, P=0.001) were found to affect the recurrence risk. While MTHFR homozygote genotype did not have an effect on recurrence risk in all patients, increased risk was observed in lymph node-positive subgroup (OR =4.271; 95% CI 1.515–12.023; P=0.006). Adjusting for age, tumor size (T), and node status (N), MTHFR homozygote genotype had more statistically significant risk for recurrence (OR =3.255; 95% CI 1.047–10.125; P=0.041). Conclusion MTHFR TT genotype was found to be associated with increased recurrence risk in patients with lymph node-positive breast cancer.
Collapse
Affiliation(s)
- Ali Suner
- Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey
| | - Hakan Buyukhatipoglu
- Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey
| | - Gokmen Aktas
- Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey
| | - Tulay Kus
- Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey
| | - Mustafa Ulasli
- Department of Medical Biology, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey
| | - Serdar Oztuzcu
- Department of Medical Biology, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey
| | - Mehmet Emin Kalender
- Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey
| | - Alper Sevinc
- Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey
| | - Seval Kul
- Department of Biostatistics, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey
| | - Celaletdin Camci
- Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, University of Gaziantep, Gaziantep, Turkey
| |
Collapse
|
9
|
Fang DH, Ji Q, Fan CH, An Q, Li J. Methionine synthase reductase A66G polymorphism and leukemia risk: evidence from published studies. Leuk Lymphoma 2014; 55:1910-4. [PMID: 24261678 DOI: 10.3109/10428194.2013.867492] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Methionine synthase reductase (MTRR) is required for the reductive methylation of cobalamin, which is the functional cofactorial form of methionine synthase (MS) in the remethylation of homocysteine to methionine. The MTRR A66G (rs1801394) polymorphism is found to be associated with decreased enzyme affinity for MTR, the gene that encodes MS, and has been widely investigated for cancer risk, including leukemia. However, the conclusions of epidemiological studies have always been contradictory. To further clarify the association of MTRR A66G polymorphism with the risk of leukemia, this meta-analysis was performed for 2913 cases and 4764 controls. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of associations. Pooled ORs were determined for the co-dominant model (GG vs. AA, AG vs. AA), dominant model (GG + AG vs. AA) and recessive model (GG vs. AA+ AG), respectively. No significant associations were found for all comparisons in the overall pooled analysis. However, the results of stratified analyses revealed that MTRR A66G GG genotype was associated with decreased leukemia risk in the Caucasian population, in children and for acute lymphoblastic leukemia (ALL). In contrast, increased risk was observed in the Asian population and for acute myeloid leukemia (AML). This meta-analysis suggests that MTRR A66G GG is associated with decreased risk of leukemia in a Caucasian population and in children, especially for ALL.
Collapse
Affiliation(s)
- Dai-Hua Fang
- Central Laboratory, Xuzhou Children's Hospital , Xuzhou, Jiangsu Province , China
| | | | | | | | | |
Collapse
|
10
|
Liu NQ, Stingl C, Look MP, Smid M, Braakman RBH, De Marchi T, Sieuwerts AM, Span PN, Sweep FCGJ, Linderholm BK, Mangia A, Paradiso A, Dirix LY, Van Laere SJ, Luider TM, Martens JWM, Foekens JA, Umar A. Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer. J Natl Cancer Inst 2014; 106:djt376. [PMID: 24399849 PMCID: PMC3952199 DOI: 10.1093/jnci/djt376] [Citation(s) in RCA: 66] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Background Clinical outcome of patients with triple-negative breast cancer (TNBC) is highly variable. This study aims to identify and validate a prognostic protein signature for TNBC patients to reduce unnecessary adjuvant systemic therapy. Methods Frozen primary tumors were collected from 126 lymph node–negative and adjuvant therapy–naive TNBC patients. These samples were used for global proteome profiling in two series: an in-house training (n = 63) and a multicenter test (n = 63) set. Patients who remained free of distant metastasis for a minimum of 5 years after surgery were defined as having good prognosis. Cox regression analysis was performed to develop a prognostic signature, which was independently validated. All statistical tests were two-sided. Results An 11-protein signature was developed in the training set (median follow-up for good-prognosis patients = 117 months) and subsequently validated in the test set (median follow-up for good-prognosis patients = 108 months) showing 89.5% sensitivity (95% confidence interval [CI] = 69.2% to 98.1%), 70.5% specificity (95% CI = 61.7% to 74.2%), 56.7% positive predictive value (95% CI = 43.8% to 62.1%), and 93.9% negative predictive value (95% CI = 82.3% to 98.9%) for poor-prognosis patients. The predicted poor-prognosis patients had higher risk to develop distant metastasis than the predicted good-prognosis patients in univariate (hazard ratio [HR] = 13.15; 95% CI = 3.03 to 57.07; P = .001) and multivariable (HR = 12.45; 95% CI = 2.67 to 58.11; P = .001) analysis. Furthermore, the predicted poor-prognosis group had statistically significantly more breast cancer–specific mortality. Using our signature as guidance, more than 60% of patients would have been exempted from unnecessary adjuvant chemotherapy compared with conventional prognostic guidelines. Conclusions We report the first validated proteomic signature to assess the natural course of clinical TNBC.
Collapse
Affiliation(s)
- Ning Qing Liu
- Affiliations of authors: Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands (NQL, MPL, MS, RBHB, TDM, AMS, JWMM, JAF, AU); Department of Neurology (CS, TML) and Postgraduate School of Molecular Medicine (NQL, RBHB, TDM, AMS, JWMM, JAF, AU), Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Radiation Oncology (PNS) and Department of Laboratory Medicine (FCGJS), Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden (BKL); Department of Oncology/Pathology, Karolinska Institute, Stockholm, Sweden (BKL); Clinical Experimental Oncology Laboratory, National Cancer Centre Giovanni Paolo II, Bari, Italy (AM, AP); Translational Cancer Research Unit, Oncology Center, GZA Hospitals St-Augustinus, Antwerp, Belgium (LYD, SJVL); Netherlands Proteomics Centre, Utrecht, The Netherlands (NQL, AU); Cancer Genomics Centre, Utrecht, The Netherlands (MS, AMS, JWMM, JAF, AU); Center for Translational Molecular Medicine, Eindhoven, The Netherlands (RBHB, JAF, AU)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|